real-world data

Original Research

Evaluating the Number of Cellular and/or Tissue-Based Product Applications Required to Treat Diabetic Foot Ulcers and Venous Leg Ulcers in Non-Hospital Outpatient Department Settings

08/09/2024

Shaun Carpenter , MD, FAPWCA, CWSP;

Angelina Ferguson , DNP, FNP, CWS;

Devinna Bahadur , DNP, AGACNP-BC, MSN-ED;

Amanda Estapa , ACNP-BC, CWS;

Jamie Bahm , RHIA, CCS;

Objective: To evaluate how the number of cellular and/or tissue-based product applications affect healing and wound area reduction rates of diabetic foot ulcers and venous leg ulcers.

Objective: To evaluate how the...

08/09/2024

Wounds

Editorial Message

Placing the Emphasis on Real-world Data

11/01/2022

John C Lantis II

Dr. John C. Lantis II, Clinical Editor, considers the importance of--and difficulty in collecting--real-world data related to patients outcomes.

Dr. John C. Lantis II, Clinical...

11/01/2022

Wounds

Guest Editorial

We Can Help Drive Acceptance of Real-World Evidence

04/01/2022

Marcia Nusgart, RPh

Now is a unique time for clinicians to articulate the realities and complexities of wound care.

Now is a unique time for...

04/01/2022

Wound Management & Prevention

Videos

Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings

03/18/2021

Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...

Daniel Geynisman, MD, discusses...

03/18/2021

Journal of Clinical Pathways

Videos

Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC

03/18/2021

Journal of Clinical Pathways

Conference Coverage

Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC

02/03/2021

Journal of Clinical Pathways

Videos

High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access

01/20/2021

Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.

Arjun Gupta, MD, discusses...

01/20/2021

Journal of Clinical Pathways

Conference Coverage

Lenvatinib Effective for Unresectable HCC in the Real-World Setting

01/16/2021

Journal of Clinical Pathways

Conference Coverage

NCCN Guideline Adherence Associated With Improved Patient Outcomes in Anal Cancer

01/15/2021

Journal of Clinical Pathways

Videos

Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML

01/14/2021

Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.

Amer Zeidan, MBBS, MHS,...

01/14/2021

Journal of Clinical Pathways